<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23D04EC2-3A05-4711-B472-F29894825709"><gtr:id>23D04EC2-3A05-4711-B472-F29894825709</gtr:id><gtr:name>Institute of Zoology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23D04EC2-3A05-4711-B472-F29894825709"><gtr:id>23D04EC2-3A05-4711-B472-F29894825709</gtr:id><gtr:name>Institute of Zoology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/572042EC-CCDD-43EC-ADA9-8ECA3B62C42B"><gtr:id>572042EC-CCDD-43EC-ADA9-8ECA3B62C42B</gtr:id><gtr:firstName>Gerard</gtr:firstName><gtr:surname>Graham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9733E295-10A9-4148-9CB1-BC133BEE52E9"><gtr:id>9733E295-10A9-4148-9CB1-BC133BEE52E9</gtr:id><gtr:firstName>Sally</gtr:firstName><gtr:surname>Macintyre</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EEE5331C-7D11-4578-BAC5-788C990A6C47"><gtr:id>EEE5331C-7D11-4578-BAC5-788C990A6C47</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>McInnes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BD6339DF-6706-4458-ACAD-49C246900497"><gtr:id>BD6339DF-6706-4458-ACAD-49C246900497</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:otherNames>F</gtr:otherNames><gtr:surname>Dominiczak</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/54BFDEDC-CB9B-4DED-9910-276995C85774"><gtr:id>54BFDEDC-CB9B-4DED-9910-276995C85774</gtr:id><gtr:firstName>Jim</gtr:firstName><gtr:surname>Cassidy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/599807B2-C178-45E6-8C5F-7A6617273BD5"><gtr:id>599807B2-C178-45E6-8C5F-7A6617273BD5</gtr:id><gtr:firstName>Miles</gtr:firstName><gtr:otherNames>Douglas</gtr:otherNames><gtr:surname>Houslay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801687"><gtr:id>55A5A525-758E-404E-B0DB-9C6B32FB8BEB</gtr:id><gtr:title>DPFS Resource Request (University of Glasgow)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801687</gtr:grantReference><gtr:abstractText>The development of new treatments for a range of diseases requires both an ability to understand the disease as well as an ability to take this understanding and to use it for the development of new therapies. We have been active in this area and have moved, in a number of disease areas, from basic research to therapies which are almost at the point of being of patient benefit. We now wish to develop these therapies further and to take them to the stage at which they will be accepted as being of sufficient value for further clinical trials. To do this we need the help of experts who will be involved in managing these sometimes very complex projects. We have 3 main disease areas that we are interested in: cancer, heart disease and inflammatory diseases such as diseases of joints and lungs. These experts will develop our projects and will ensure that their potential entry into clinical practice is carefully and efficiently handled. In addition, some of the therapeutics we are interested in are experimental and we are also requesting some items of equipment which will be important in helping us to assess the effectiveness of these therapies.</gtr:abstractText><gtr:technicalSummary>Cancer, Cardiovascular and Inflammation are the three areas of strategic priority for translational medicine within the University of Glasgow. These represent priority areas for basic research as well as for translational and clinical research and we aim to foster bi-directional bench to bedside and population ethos within our university. As a result of our existing collaborative efforts, we are now at an advanced stage of development of a number of potential therapeutics which show promise in each of these 3 key areas. We believe that with the help of an integrated project management team and strategic advisory group we will be able to expedite the translation of our research findings in each of the above areas into the clinic. We request 3 Translational Research Managers, working in conjunction with a Translational Research Advisory Group, to provide experienced and dedicated project management support for translational projects in each of our three priority areas; to develop and support the interfaces between these areas; to develop and support the interface with researchers in the MRC Social and Public Health Sciences Unit; and to facilitate the basic to translational pipeline within our key thematic areas. In addition, we request small items of capital equipment to be used across translational medicine projects, including Laser Dissection Microscopy, 2 Ultrasound Scanners, a Dimension Xpand Plus Analyser, an Endo-PAT2000 and a Zeiss LSM 5 Exciter Confocal Microscope. The pieces of equipment would be immediately employed for rapid gains thus further enhancing our international competitiveness in key fields.</gtr:technicalSummary><gtr:fund><gtr:end>2011-05-17</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-05-18</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>240801</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>BMS Academic Collaboration</gtr:description><gtr:id>468866D6-CDF9-40A7-9D39-84F5892A990D</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>iZ2T6TAvWo2-1</gtr:outcomeId><gtr:piContribution>TO explore the role of abatacept in tolerance induction</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>BT Cure</gtr:description><gtr:id>5100C182-45C2-42DC-A6FE-F99D4B68C54B</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>qCUetm2RT9H-1</gtr:outcomeId><gtr:partnerContribution>Intellectual partnership and idea promotion</gtr:partnerContribution><gtr:piContribution>WP Leader in IMI consortium</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Unit for Lifelong Health and Ageing</gtr:department><gtr:description>1946 Study - novel cardiovascular risk markers</gtr:description><gtr:id>01FE4711-AEC7-49D3-8F96-3AF81A876488</gtr:id><gtr:impact>Work is ongoing with no outcomes as yet. 
The collaboration is multi-disciplinary including the MRC Unit, metabolic medicine, cardiovascular and epidemiology.</gtr:impact><gtr:outcomeId>AEBh1w2TkjQ-1</gtr:outcomeId><gtr:piContribution>We are conducting novel biomarker assessments in the 1946 study. We are measuring several analytes in over 2200 samples.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zurich</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>FP7 Masterswitch</gtr:description><gtr:id>65C1C283-BB92-4F0B-937D-E1AFE103A1D1</gtr:id><gtr:impact>Not as yet.</gtr:impact><gtr:outcomeId>jZJa1dwPvDp-1</gtr:outcomeId><gtr:partnerContribution>Information sharing and technical advice</gtr:partnerContribution><gtr:piContribution>I am WP leader on this FP7 grant which is exploring the role of innate immune activation in rheumatoid arthritis -aiming to take mechanism to new therapeutics.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>SABRE - predictors of cardiometabolic disease in different ethnic groups.</gtr:description><gtr:id>02CA49FD-87A3-417E-9477-0FEA41C521AA</gtr:id><gtr:impact>Ongoing work on a variety of biomarkers and outputs include oral presentation at European Association for Study of Diabetes: we anticipate several papers arising from this work.
Yes multi-disciplinary including biochemistry; metabolic medicine; epidemiology and public health sciences.</gtr:impact><gtr:outcomeId>e6ReMUEZAND-1</gtr:outcomeId><gtr:piContribution>We conducted biobank analyses incude HBA1c, insulin, and other novel biomarkers on over 2000 samples.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Causal Analyses in Translational Epidemiology</gtr:department><gtr:description>ALSPAC - utility of biomarkers in adolescent non-alcoholic fatty liver disease</gtr:description><gtr:id>A2A8F889-2763-481F-BA28-A903873355C0</gtr:id><gtr:impact>There are no outcomes so far, but all the data on over 3500 adolescents on a range of biomarkers will contribute to several papers of clinical relevance.
The collaboration was multi-disciplinary and included biochemistry, metabolic medicine, epidemiology and public health.</gtr:impact><gtr:outcomeId>Kb63SrB4Z23-1</gtr:outcomeId><gtr:piContribution>The research is investigating the utility of biomarkers for non-alcoholic fatty liver disease in adolescents. We conducted liver function and novel biomarker tests in 17 year olds.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MVLS Industry Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1CCE0342-AC3F-4ABB-B463-4FA70B644576</gtr:id><gtr:impact>Using various networks several 100 biomedical, life sciences and veterinary professionals from industry, government and public sector organisations were invited the University of Glasgow's College of Medical, Veterinary and Life Sciences first Industry Day. After keynote presentations from Dr Patrick Vallance (GSK) and Dr Ruth McKernan (Pfizer) participants had the opportunity, via speed-dating presentations and poster sessions to learn more about our research capabilities. www.gla.ac.uk/colleges/mvls/industryday/

Non-confidential technical datasheets prepared for the event provide ready-made marketing materials which have been used on numberous occasions post the event to showcase our research capability.
The event raised awareness of the breadth of research capability across our College encouraging new collaborations and alliances to be explored.</gtr:impact><gtr:outcomeId>X4iZEbaQpsA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>563805</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Efficacy and Mechanism Evaluation Programme</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>6EC4D8AA-BF93-412E-B162-2664226BE2AA</gtr:id><gtr:outcomeId>BTtQDfW7dyy</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Concept</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>MRC Headoffice</gtr:fundingOrg><gtr:fundingRef>MC-PC-13063</gtr:fundingRef><gtr:id>EA87AB1E-D9C4-4F6C-BE7C-094DF7CDE74C</gtr:id><gtr:outcomeId>56d9c6bb6ad6e5.77020210</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Concept</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>MRC Headoffice</gtr:fundingOrg><gtr:fundingRef>MC-PC-15039</gtr:fundingRef><gtr:id>B00B3691-9613-456F-8010-F43C844B568A</gtr:id><gtr:outcomeId>56d9c7bf9b5100.19964116</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3323536</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DCS</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001147</gtr:fundingRef><gtr:id>EADD3AC9-26AE-4821-811C-3E6153E47EDD</gtr:id><gtr:outcomeId>gDnjoGZME6U</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>726292</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G100791</gtr:fundingRef><gtr:id>1AABE5ED-3352-4672-911B-5BED5FAF682F</gtr:id><gtr:outcomeId>tHK3zsEEuJr</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>481903</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/AstraZeneca Mechanisms of Disease</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B4A66358-E44C-42C8-A12D-13FBA49539D2</gtr:id><gtr:outcomeId>skkwr93F5fF</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5ED56542-A362-40F1-902F-F357E99E1EBD</gtr:id><gtr:title>Characterization of the anticollagen antibody response in a new model of chronic polyarthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f84f3b4c51f42f738c70e796314629e"><gtr:id>1f84f3b4c51f42f738c70e796314629e</gtr:id><gtr:otherNames>Conigliaro P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>546a1cbf8f7069.68191208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F96B3EB-E75B-4F03-B1C9-39CE552D50AE</gtr:id><gtr:title>Putative existence of reciprocal dialogue between Tfh and B cells and its impact on infectious and autoimmune disease.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cc237bc1bda121f8379386fc3b61d31"><gtr:id>9cc237bc1bda121f8379386fc3b61d31</gtr:id><gtr:otherNames>Patakas A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>546a1cbf696476.38851178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB32578C-C465-46E2-9DB3-D847574F47A5</gtr:id><gtr:title>Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25b16b47c3d37f338fcfc6a6de9848c0"><gtr:id>25b16b47c3d37f338fcfc6a6de9848c0</gtr:id><gtr:otherNames>Platt AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>546a1d5643ed60.59067515</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801687</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>